Diving Into Adjuvant Approaches in Early-Stage Resectable NSCLC: PD-L1 Expression and Genomic Considerations
Corey J. Langer, MD, FACP, discusses findings from the IMpower010 and KEYNOTE-091 studies, which examined immunotherapy in NSCLC.
United States University Of Pennsylvania Amgen Genentech Roche Ariad Takeda Genentech Roche Lilly Incyte
Source: onclive.com